瑞科(02179.HK)逆同業挫14%再創上市新低 市前有涉資逾1,700萬元大手上板
瑞科生物-B(02179.HK)市前有一宗150萬股以每股11.44元(較上週五收市折讓逾18%)非自動對盤上板,涉資1,716萬元;該股今早逆同業再創上市新低,最低見11.9元,半日收12元,急挫14%,一向薄弱成交增至157.4萬股,涉資1,808萬元。
瑞科是內地一家於2012年創立的疫苗公司,其主要專注於HPV候選疫苗的研發。股份於去年3月底以每股24.8元來港上市,合共發售3,085.45萬股,並已引入包括揚子江香港、Harvest、SCHP及紅杉資本中國轄下Sequoia Capital China Growth四名基石投資合共認購1,671.85萬股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.